# COAG (Hemab Therapeutics Holdings, Inc.) - SEC EDGAR Financial Statements

> Hemab Therapeutics Holdings, Inc. reported $442.7M in total assets through September 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/COAG
- Markdown: https://convexityos.com/fundamentals/COAG.md
- SEC CIK: 0002114044
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 20, 2026, 05:24 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002114044&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Sep 30, 2026 |
| Operating Income | FY 2026 | -- | Operating profit |
| Net Income | FY 2026 | -- | GAAP bottom line |
| Diluted EPS | FY 2026 | -- | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $430.2M | Total debt: $965K |

## Income Statement

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $24.64M | $20.34M | $19.46M | $14.55M | $12.87M | $14.10M |
| Selling, General & Admin | $5.12M | $5.74M | $4.15M | $2.50M | $3.18M | $2.46M |
| Total Operating Expenses | $29.76M | $26.08M | $23.61M | $17.05M | $16.06M | $16.56M |
| **Operating Income** | -$29.76M | -$26.08M | -$23.61M | -$17.05M | -$16.06M | -$16.56M |
| **EBITDA** | -$29.68M | -$26.00M | -$23.54M | -$16.98M | -$15.98M | -$16.48M |
| Interest Income | $3.38M | $2.86M | $1.22M | $215K | $335K | $473K |
| Income Before Tax | -$26.61M | -$24.05M | -$22.68M | -$16.97M | -$12.21M | -$15.50M |
| Income Tax Expense | $693K | $97K | $12K | $98K | $4.0K | -$190K |
| **Net Income** | -$27.30M | -$24.15M | -$22.69M | -$17.07M | -$12.21M | -$15.31M |
| Basic EPS | -$0.58 | -$0.80 | -$1.09 | -$18.04 | -$12.91 | -$0.74 |
| **Diluted EPS** | -$0.58 | -$0.80 | -$1.09 | -$18.04 | -$12.91 | -$0.74 |
| Basic Shares Outstanding | 46.7M | 30.1M | 20.8M | 946.0K | 946.0K | 20.8M |
| Diluted Shares Outstanding | 46.7M | 30.1M | 20.8M | 946.0K | 946.0K | 20.8M |

## Balance Sheet

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $239.1M | $237.4M | $49.86M | $87.97M |
| Short-Term Investments | $191.1M | $220.1M | $113.7M | $97.51M |
| **Cash & Short-Term Investments** | $430.2M | $457.5M | $163.5M | $185.5M |
| **Total Current Assets** | $438.2M | $464.0M | $169.4M | $192.6M |
| Property, Plant & Equipment, Net | $555K | $596K | $648K | $609K |
| Other Non-Current Assets | $3.15M | $2.29M | $4.24M | $531K |
| **Total Non-Current Assets** | $4.55M | $3.78M | $5.83M | $2.23M |
| **Total Assets** | $442.7M | $467.8M | $175.3M | $194.8M |
| Accounts Payable | $5.95M | $6.23M | $5.68M | $5.73M |
| Other Current Liabilities | $1.20M | $990K | $2.66M | $340K |
| **Total Current Liabilities** | $12.94M | $12.94M | $13.19M | $10.68M |
| **Total Non-Current Liabilities** | $503K | $566K | $519K | $573K |
| **Total Liabilities** | $13.44M | $13.51M | $13.71M | $11.25M |
| **Total Debt (incl. Leases)** | $965K | $1.03M | $1.06M | $1.22M |
| Retained Earnings | -$256.0M | -$228.7M | -$204.5M | -$181.9M |
| Accumulated Other Comp. Income | -$2.65M | -$2.75M | -$439K | $175K |
| **Total Stockholders' Equity** | $429.3M | $454.3M | -$198.6M | -$176.6M |
| Total Equity | $429.3M | $454.3M | -$198.6M | -$176.6M |

## Cash Flow Statement

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$27.30M | -$24.15M | -$22.69M | -$17.07M | -$12.21M | -$15.31M |
| Depreciation & Amortization | $75K | $75K | $73K | $76K | $77K | $75K |
| Change in Payables | -$280K | $550K | -$52K | $872K | -$2.32M | $2.88M |
| **Operating Cash Flow** | -$28.29M | -$22.64M | -$21.58M | -$16.39M | -$15.33M | -$13.03M |
| Capital Expenditure | -$34K | -$23K | -$112K | $0 | $0 | -$16K |
| **Free Cash Flow** | -$28.32M | -$22.66M | -$21.70M | -$16.39M | -$15.33M | -$13.05M |
| Purchases of Investments | $0 | -$132.5M | -$15.73M | $0 | $0 | -$19.95M |
| **Investing Cash Flow** | $30.10M | -$107.4M | -$15.85M | $0 | $21.50M | -$5.99M |
| **Financing Cash Flow** | $47K | $317.6M | -$460K | -$30K | -$30K | -$29K |
| **Net Change in Cash** | $1.78M | $187.5M | -$38.11M | -$16.43M | $6.14M | -$19.06M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 |
| --- | --- | --- | --- | --- | --- | --- |
| Current Ratio | 33.86x | 35.85x | 12.85x | -- | -- | -- |
| Quick Ratio | 33.25x | 35.34x | 12.40x | -- | -- | -- |
| Debt to Equity | 0.00x | 0.00x | -- | -- | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
